Supernus Pharmaceuticals, Inc. is a mid-cap biopharmaceutical company specializing in the treatment of central nervous system diseases. The company pursues growth by advancing both commercial and pipeline products, with a focus on differentiated therapies for epilepsy, ADHD, Parkinson's disease, and related conditions. Its strategy centers on expanding its CNS portfolio and leveraging established distribution channels to maintain a competitive presence in the specialty pharmaceutical sector.The firm generat ...

Supernus Pharmaceuticals FY Conference Summary Company Overview - **Company**: Supernus Pharmaceuticals (NasdaqGM: SUPN) - **Date of Conference**: March 11, 2026 - **Key Speaker**: Jack A. Khattar, President and CEO Key Accomplishments in 2025 - **Sage Therapeutics Acquisition**: Significant milestone for the company, enhancing the product portfolio with the addition of Zurzuvae, which is expected to be a major growth driver [2][4] - **FDA Approvals and Product Launches**: Successful launch of ONAPGO, which exceeded expectations and contributed to revenue growth [4][5] - **Record Revenue**: 2025 marked a record year for revenue, driven by the transition from legacy products to new offerings [4] Growth Drivers - **Product Portfolio**: Four main growth drivers identified: - **Qelbree**: ADHD treatment, showing 21% growth in 2025 and 18% growth in Q4 [5][23] - **Gocovri**: Parkinson's treatment, with 14% growth in prescriptions [37] - **Zurzuvae**: Postpartum depression treatment, unique in its rapid efficacy [38] - **ONAPGO**: Strong demand despite supply constraints, with forms submitted increasing from 1,300 to 1,800 [10][49] Market Performance - **Stock Performance**: The stock increased by 80% over a six-month period, reflecting market recognition of the company's portfolio reconfiguration [12] - **Market Share**: Qelbree achieved 931,000 prescriptions in 2025, indicating significant market potential within a total market of 111 million prescriptions [27] Supply Chain and Production - **Supply Constraints**: ONAPGO faced supply issues due to overwhelming demand and shared production lines with other clients [48] - **Future Supply Plans**: Plans to secure a second source of supply by 2027 to alleviate production constraints [49] Financial Guidance for 2026 - **Revenue Expectations**: Projected revenue between $840 million and $870 million, representing a growth of 32%-37% [50] - **Operating Earnings**: Expected to remain flat year-over-year at $140 million to $170 million due to ongoing investments in new products [58] Research and Development Pipeline - **SPN-817**: Phase 2 trial for epilepsy, expected data in 2027 [68][72] - **SPN-820**: Phase 2 trial for major depressive disorder, anticipated to recruit faster than epilepsy trials [74] - **SPN-443**: Early-stage stimulant for ADHD, with ongoing studies to assess its safety and efficacy [78] Strategic Outlook - **M&A and R&D**: The company emphasizes the importance of both mergers and acquisitions and research and development for future growth [93] - **Market Education**: Ongoing efforts to educate physicians and patients about new treatment options, particularly for postpartum depression [61][66] Conclusion - **Future Potential**: The company believes it is at the beginning of a transformative phase, with a clean balance sheet and a focus on both organic growth and strategic acquisitions [93]

Supernus Pharmaceuticals FY Conference Summary Company Overview - **Company**: Supernus Pharmaceuticals (NasdaqGM:SUPN) - **Date of Conference**: March 02, 2026 - **Key Speakers**: Jack Khattar (CEO), Timothy C. Dec (CFO) Key Points Industry and Company Position - Supernus is positioned differently today with a diverse portfolio of products, moving beyond reliance on a single product [2] - The company has four growth products and is experiencing accelerated growth with an exciting pipeline [2][3] Product Performance - **ONAPGO**: Recently reinitiated patient treatment after resolving supply constraints. The product has strong demand, evidenced by 500 patient forms submitted during supply issues [4][5][6] - **ZURZUVAE**: Launched with a focus on educating women about postpartum depression, aiming to increase awareness and usage [51][52] - **Qelbree**: Continues to perform well, with a stable mix of adult and pediatric prescriptions. The product is underutilized in the non-stimulant segment, presenting significant growth potential [42][43][44] Financial Guidance - ONAPGO revenue guidance is set between $45 million and $70 million, influenced by supply, demand, and fulfillment rates [24][26] - Peak sales for ONAPGO may exceed initial estimates of $200 million to $300 million due to overwhelming demand [38][40] Patient Demand and Market Dynamics - Demand for ONAPGO is strong, with patients willing to wait through supply disruptions rather than switch to competitors [10][12] - The company anticipates a conversion rate of 15%-25% from patient forms to actual patients, which is typical in the industry [22] Pipeline and Future Developments - The company is optimistic about its pipeline, with promising assets in Phase 2b studies expected to yield data in 2027 [59] - Supernus is actively pursuing business development opportunities, focusing on revenue-generating assets and later-stage products [58] Manufacturing and Supply Chain - A second supplier is expected to come online in 2027, which will help mitigate supply issues [29][32] - The company is working to streamline the patient initiation process to reduce friction points in fulfillment [23] Market Education and Awareness - Significant investment in educating healthcare providers and patients about ZURZUVAE and its benefits over traditional SSRIs [51][52][55] - The company aims to establish ZURZUVAE as the standard of care for postpartum depression [55] Conclusion - Supernus Pharmaceuticals is navigating a transformative phase with a robust product pipeline and strategic focus on market education and patient demand. The company is well-positioned for growth in the coming years, particularly with ONAPGO and ZURZUVAE.

Core Insights - Supernus Pharmaceuticals achieved record revenues of $719 million in 2025, driven by a 40% revenue increase from four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now account for 76% of total revenues [4] - The company successfully integrated the acquisition of Sage Therapeutics, adding ZURZUVAE to its portfolio and establishing a presence in the women's health and postpartum depression markets [4] - Projected total revenues for 2026 are estimated to be between $840 million and $870 million, with ONAPGO expected to contribute $45 million to $70 million as supply stabilizes [4] Strategic Performance and Operational Context - The company managed ONAPGO supply constraints by prioritizing existing patient maintenance and preparing to resume new patient initiations in early 2026 [4] - Qelbree's fourth-quarter net sales lagged behind prescription growth due to an unexpected $4 million PBM bill for the full year of 2025 [4] - The company maintains a disciplined R&D approach, retaining high-potential Sage assets for internal development while seeking external partnerships for early-stage pipeline candidates [4] 2026 Outlook and Strategic Priorities - The strategic focus for 2026 includes clearing the ONAPGO patient backlog and transitioning to a second manufacturing supplier by 2027 to ensure long-term capacity [4] - The M&A strategy is focused on revenue-generating assets or late-stage pipeline candidates that could launch between 2027 and 2031 [4] - Clinical timelines for SPN-820 (depression) and SPN-817 (epilepsy) target top-line data readouts in 2027, with SPN-820 expected to recruit faster due to the indication type [4] Financial Performance - The company recorded $73 million in acquisition-related costs and $50 million in incremental operating costs associated with the Sage Therapeutics transaction in 2025 [4] - A GAAP operating loss of $62.3 million was reported for 2025, primarily due to one-time acquisition expenses and higher intangible asset amortization for new products [4] Market Opportunities - A 700-patient queue for ONAPGO awaiting benefit verification represents a significant near-term revenue conversion opportunity as supply resumes [6] - High demand for ONAPGO exists, but the conversion of 1,800 enrollment forms to active patients is subject to typical specialty pharmacy attrition and reimbursement hurdles [6]

Core Insights - Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, marking a 21.5% year-over-year increase and exceeding the Zacks Consensus Estimate by 7.57% [1] - The company's EPS for the same quarter was $0.92, a significant increase from $0.75 a year ago, resulting in an EPS surprise of 228.57% compared to the consensus estimate of $0.28 [1] Revenue Performance - Trokendi XR generated $8.4 million in net product sales, below the average estimate of $5.81 million, reflecting a year-over-year decline of 43.2% [4] - Oxtellar XR reported $6.8 million in net product sales, surpassing the average estimate of $5.75 million, but showing a year-over-year decrease of 48.5% [4] - APOKYN achieved $9.6 million in net product sales, slightly below the average estimate of $9.93 million, with a year-over-year decline of 52.2% [4] - Qelbree's net product sales were $81 million, below the average estimate of $87.72 million, but showing an 8.9% year-over-year increase [4] - Collaboration revenue from ZURZUVAE was $32.8 million, exceeding the average estimate of $28.05 million [4] - Total net product sales amounted to $158.1 million, below the average estimate of $193.42 million, representing a year-over-year decline of 5% [4] - Royalty, licensing, and other revenues reached $20.7 million, significantly above the average estimate of $3.25 million, with a year-over-year increase of 166.6% [4] - ONAPGO net product sales were $8.9 million, exceeding the average estimate of $6.1 million [4] - GOCOVRI generated $38.6 million in net product sales, slightly below the average estimate of $42.64 million, with a year-over-year increase of 4.6% [4] Stock Performance - Supernus shares have returned +3.1% over the past month, contrasting with a -1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million in 2025, representing a 27% increase compared to the previous year [17] - The company reported a GAAP net loss of $38.6 million for 2025, compared to a net earnings of $73.9 million in 2024 [18] - For the fourth quarter of 2025, total revenue was $211.6 million, a 21% increase year-over-year [13] Business Line Data and Key Metrics Changes - Revenues from four growth products (Qelbree, Proquarius, Zurzuvae, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales of $17.3 million for its first year [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [7] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [6] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by over 150% [8] Company Strategy and Development Direction - The company is focused on corporate development and exploring strategic opportunities to strengthen its position in the CNS market through revenue-generating products and late-stage pipeline candidates [11] - Supernus aims to continue growing its core business despite the loss of exclusivity on Trokendi XR and Oxtellar XR [4] - The company plans to maintain a diversified portfolio of growth products to mitigate reliance on any single product [78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [20] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [20] - Management highlighted the importance of resolving supply constraints for ONAPGO to meet demand and clear backlogs [29] Other Important Information - The company had approximately $309 million in cash equivalents and marketable securities as of December 31, 2025, down from $454 million in 2024 [19] - Supernus is actively working on R&D programs, including trials for SPN-820 and SPN-817, with data expected in 2027 [74] Q&A Session Summary Question: ONAPGO sales guidance and supplier capacity - Management confirmed that the current supplier can meet the sales guidance of $45 million to $70 million for ONAPGO through 2026, with a second supplier expected to come online in 2027 [23] Question: ONAPGO demand and backlog clearance - Management stated that the current supplier will help clear the backlog and meet ongoing demand throughout 2026 [29] Question: R&D prioritization post-Sage acquisition - Management indicated that early-stage assets will undergo preclinical work, and prioritization will be based on market opportunity and ROI [30] Question: Pricing expectations for ONAPGO - Management estimated that the average annual cost for ONAPGO could be around $100,000 per patient, depending on usage [38] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net deductions for ONAPGO to be in the range of 20% to 30%, typically higher in Q1 [67] Question: Commercial strategy for Zurzuvae - Management emphasized the need to build market awareness and confidence among physicians for Zurzuvae, while also focusing on both existing and new prescribers [60][62]

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [17] - The fourth quarter of 2025 saw total revenue of $211.6 million, a 21% increase year-over-year, with net product sales of $158.1 million [13] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales of $17.3 million for its first year [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to the same period in 2024 [7] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [6] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [8] Company Strategy and Development Direction - The company successfully executed an integrated acquisition of Sage Therapeutics and obtained FDA approval for ONAPGO, launching it in the Parkinson's market [4] - Corporate development remains a top priority, with a focus on additional strategic opportunities to strengthen future growth in CNS through revenue-generating products or late-stage pipeline candidates [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet demand for ONAPGO through existing suppliers and anticipated a smooth transition to a second supplier in 2027 [23][50] - The company expects total revenues for 2026 to range from $840 million to $870 million, with guidance assuming $45 million to $70 million in net sales from ONAPGO [20] Other Important Information - Combined R&D and SG&A expenses for 2025 were $591.8 million, up from $430.4 million in 2024, primarily due to acquisition-related costs [18] - The company had approximately $309 million in cash equivalents and marketable securities as of December 31, 2025, down from $454 million the previous year [19] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2027 [23] Question: ONAPGO demand and backlog clearance - Management indicated that the current supplier will help clear the backlog and meet ongoing demand throughout 2026 [29] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, and prioritization will be based on market opportunity and ROI [30] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [16] - For Q4 2025, total revenue was $211.6 million, a 21% increase year-over-year, and a 34% increase when excluding net product sales of Trokendi XR and Oxtellar XR [13][16] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [17] - Adjusted operating earnings for the full year 2025 were $158.7 million, down from $183.7 million in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales for its first year at $17.3 million [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [6] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [5] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [6] - GOCOVRI reached net sales of $146 million for the full year 2025, a 12% increase compared to 2024 [10] Company Strategy and Development Direction - The company aims to continue growing its core business while exploring corporate development opportunities to strengthen its position in the CNS market [11][76] - Supernus is focused on revenue-generating products and late-stage pipeline candidates, with a strategic emphasis on expanding its portfolio beyond CNS into areas like women's health [72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [19] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [19] - Management highlighted the importance of maintaining a strong balance sheet with no debt, providing financial flexibility for future growth opportunities [18] Other Important Information - The company initiated a Phase IIb trial for SPN-820 and is progressing with ongoing trials for SPN-817, with data expected in 2027 [11][71] - Supernus has made significant investments in R&D and SG&A, with combined expenses reaching $591.8 million for the full year 2025 [16] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2026 [21] Question: ONAPGO demand and patient enrollment - Management indicated that the current supplier will help clear the backlog and support new patient initiations, with ongoing processing of enrollment forms [28] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, with prioritization based on market opportunity and ROI [29] Question: Zurzuvae commercial strategy - Management emphasized the need to build market awareness and confidence among physicians to drive prescriptions for Zurzuvae [59] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]

Core Insights - Supernus Pharmaceuticals reported significant progress in 2025, achieving record total revenues and successfully launching ONAPGO for Parkinson's disease [2][4] - The company is focused on advancing its key growth products and resuming new patient initiation for ONAPGO in 2026 [2] Financial Performance - Total revenues for Q4 2025 reached $211.6 million, a 21% increase year-over-year, while full-year revenues were $719.0 million, up 9% from 2024 [4][8] - Combined revenues from the company's four growth products increased to $161.3 million in Q4 2025, representing a 45% year-over-year growth, and $521.8 million for the full year, a 40% increase [4][8] - Cash, cash equivalents, and current marketable securities totaled $308.7 million as of December 31, 2025 [4] Product Highlights - ONAPGO net product sales were $8.9 million in Q4 2025, following its U.S. launch in April 2025, with over 1,800 enrollment forms submitted by more than 540 prescribers [5] - Collaboration revenue from ZURZUVAE was $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [5] - Net sales of Qelbree increased 9% to $81.0 million in Q4 2025, while GOCOVRI sales rose 5% to $38.6 million [5] Research and Development - The company is conducting a Phase 2b study for SPN-817, a novel AChE inhibitor for epilepsy, and has initiated a Phase 2b trial for SPN-820, a treatment for major depressive disorder [6] - SPN-443, a novel stimulant for ADHD, is expected to enter Phase 1 trials in the second half of 2026 [6] Financial Guidance - For full year 2026, Supernus expects total revenues between $840 million and $870 million, with operating earnings projected at $0 million to $30 million [10] - ONAPGO net sales are anticipated to be between $45 million and $70 million, while Trokendi XR and Oxtellar XR net sales are expected to be $40 million to $50 million [10]

Core Insights - The sale of shares by Aristotle Capital Boston indicates profit-taking in Supernus Pharmaceuticals, which is operationally performing well but facing scrutiny regarding its durability and valuation [1][9]. Company Overview - Supernus Pharmaceuticals is a mid-cap biopharmaceutical company focused on therapies for central nervous system (CNS) disorders, with a market capitalization of $2.7 billion and a revenue of $681.5 million over the trailing twelve months (TTM) [4][5]. - The company reported a net income loss of $19.1 million TTM, indicating challenges in profitability despite operational momentum [4][10]. Recent Developments - Aristotle Capital Boston reduced its holdings in Supernus by 503,122 shares, bringing its total position down to 305,273 shares valued at $14.6 million as of September 30 [2]. - The shares sold were valued at approximately $10.9 million, reflecting a strategic reallocation of capital rather than a loss of confidence in the company [2][11]. Financial Performance - Supernus reported a 9% year-over-year revenue increase in the third quarter, totaling $192.1 million, driven by over 50% growth from its four key products [10]. - The company raised its full-year revenue guidance, indicating confidence in its near-term execution despite facing rising expenses and integration risks [10][11]. Market Position - Supernus shares have increased by approximately 31% over the past year, significantly outperforming the S&P 500, which rose about 13% in the same period [3]. - The company’s focus on specialty conditions and established distribution channels supports its competitive position in the U.S. CNS therapeutics market [5][8].